Resources & Tools

Glossary

A comprehensive gene therapy and nanomedicine glossary — 249 terms across 15 topics, from transfection methods and viral vectors to characterisation, safety and regulatory translation, plus 97 abbreviations.

249 terms · 97 abbreviations

Transfection & Gene Delivery Methods13

Transfection: The deliberate introduction of nucleic acids (DNA, RNA, siRNA, miRNA, or oligonucleotides) into eukaryotic cells through non-viral methods. This process temporarily or stably alters gene expression to achieve therapeutic, research, or biotechnological objectives. Transfection can be transient (temporary expression) or stable (permanent integration into the genome).
Gene Delivery: The comprehensive process of transporting genetic material into target cells or tissues using various vectors and techniques. Effective gene delivery requires overcoming multiple biological barriers including cellular uptake, endosomal escape, cytoplasmic trafficking, and nuclear entry while maintaining cargo integrity and minimising toxicity.
Transduction: The process of introducing genetic material into cells using viral vectors. Unlike transfection, transduction exploits the natural infection mechanisms of viruses that have been engineered to be replication-defective and safe. Transduction typically achieves higher efficiency than non-viral methods but raises concerns about immunogenicity and insertional mutagenesis.
Transfection Efficiency: A quantitative measure expressed as the percentage of cells that successfully internalise and express the introduced genetic material. This metric is critical for evaluating delivery system performance and is influenced by factors including vector design, cell type, physiological conditions, and delivery method. High transfection efficiency (>80%) is often required for therapeutic applications.
Lipofection: A widely-used transfection technique employing lipid-based carriers (liposomes or lipid nanoparticles) to encapsulate and deliver nucleic acids. Cationic lipids interact electrostatically with negatively charged nucleic acids, forming lipoplexes that fuse with cell membranes. Lipofection is relatively simple, versatile across cell types, and avoids viral safety concerns, making it popular for both research and clinical applications including mRNA vaccines.
Electroporation: A physical transfection method that applies brief electrical pulses to cells, creating transient pores in the cell membrane through which nucleic acids can enter. The technique requires optimisation of voltage, pulse duration, and pulse number for each cell type. While highly efficient for many cell types, electroporation can cause significant cell death and requires specialised equipment.
Nucleofection: An advanced electroporation technology that delivers nucleic acids directly into the cell nucleus, bypassing cytoplasmic barriers. This method combines electrical parameters with cell-type-specific solutions to achieve high transfection efficiency in difficult-to-transfect cells including primary cells, stem cells, and neurons. Nucleofection significantly reduces the time between delivery and gene expression.
Magnetofection: A technique that associates nucleic acids with magnetic nanoparticles (typically iron oxide) and uses external magnetic fields to concentrate and drive the complexes into target cells. This approach enhances delivery efficiency, reduces required dosages, and enables spatial control of transfection. Magnetofection is particularly useful for hard-to-transfect cells and localised delivery applications.
Sonoporation: A method utilising ultrasound energy to create temporary pores in cell membranes, facilitating nucleic acid entry. Microbubbles are often used to enhance cavitation effects. Sonoporation is non-invasive, can target deep tissues, and shows promise for localised gene delivery in vivo, particularly for treating tumours and cardiovascular diseases.
Microinjection: Direct mechanical injection of nucleic acids into individual cells or cell nuclei using fine glass micropipettes. Though labour-intensive and low-throughput, microinjection achieves nearly 100% delivery into targeted cells and is invaluable for creating transgenic organisms, studying single-cell genetics, and fertilized egg modification.
Gene Gun (Biolistic Particle Delivery): A physical delivery method that accelerates gold or tungsten microparticles coated with DNA into cells using compressed gas. Originally developed for plant transformation, gene guns can deliver genes into tissues that are difficult to transfect by other methods, including skin for DNA vaccination.
Calcium Phosphate Transfection: A classical chemical transfection method where DNA is precipitated with calcium phosphate to form particles that cells internalise via endocytosis. This inexpensive, simple technique works well for adherent cell lines but shows high variability and lower efficiency compared to modern methods.
Cell-Penetrating Peptides (CPPs): Short amino acid sequences (typically 5-30 residues) capable of crossing cellular membranes and delivering conjugated cargo including nucleic acids, proteins, and nanoparticles. Examples include TAT peptide from HIV, penetratin, and oligoarginine sequences. CPPs enable direct cytoplasmic delivery with minimal toxicity.

Gene Therapy Fundamentals15

Gene Therapy: A revolutionary medical approach that treats or prevents disease by introducing, deleting, or modifying genetic material within a patient's cells. Gene therapy aims to correct genetic defects, provide new cellular functions, or eliminate disease-causing mechanisms. Applications span inherited disorders, cancers, infectious diseases, and cardiovascular conditions.
In Vivo Gene Therapy: Therapeutic approach where genetic material is delivered directly into the patient's body, typically through systemic or local administration. Vectors travel through biological systems to reach target tissues where they transduce cells in their native environment. This approach is less invasive but faces challenges including vector targeting, immune responses, and off-target effects.
Ex Vivo Gene Therapy: A therapeutic strategy where cells are harvested from the patient, genetically modified in laboratory conditions, expanded in culture, and then reinfused into the patient. This approach allows quality control, cell selection, and avoidance of systemic vector exposure but is more complex and expensive. Commonly used for CAR-T cell therapy and treatment of blood disorders.
Gene Editing: Precise, targeted modification of genomic DNA sequences using programmable molecular tools. Unlike traditional gene addition, gene editing can correct mutations at their original location, delete disease-causing sequences, or insert therapeutic genes at specific genomic sites. Technologies include CRISPR-Cas systems, TALENs, zinc finger nucleases, and base editors.
CRISPR-Cas9: A revolutionary gene-editing system adapted from bacterial immune mechanisms. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) uses a guide RNA to direct Cas9 nuclease to specific DNA sequences where it creates double-strand breaks. The cell's repair mechanisms then modify the targeted sequence. CRISPR enables unprecedented precision, ease of use, and multiplexed editing capabilities.
Base Editing: A refined CRISPR technology that directly converts one DNA base to another (C to T or A to G) without creating double-strand breaks. Base editors fuse catalytically impaired Cas9 to deaminase enzymes, enabling precise point mutation correction without inducing insertions, deletions, or chromosomal rearrangements that can occur with traditional CRISPR.
Prime Editing: An advanced gene-editing approach that enables precise insertions, deletions, and all base-to-base conversions without requiring double-strand breaks or donor DNA templates. Prime editors use a fusion of Cas9 nickase and reverse transcriptase, guided by prime editing guide RNAs (pegRNAs), offering unprecedented versatility for correcting genetic mutations.
Gene Augmentation Therapy: A therapeutic strategy that introduces functional copies of genes into cells to compensate for defective or missing genes. Rather than correcting the original mutation, augmentation provides an additional working copy. This approach is particularly effective for recessive genetic disorders where one functional gene copy can restore normal function.
Gene Silencing: Therapeutic reduction or elimination of specific gene expression to treat diseases caused by overactive genes, dominant-negative mutations, or toxic gain-of-function. Techniques include RNA interference (RNAi), antisense oligonucleotides, and CRISPR-based transcriptional repression (CRISPRi). Applications include cancer, viral infections, and dominant genetic disorders.
Gene Replacement Therapy: The introduction of a functional gene to replace a mutated or absent gene. This is the most straightforward gene therapy approach and has achieved clinical success in treating inherited retinal dystrophy, spinal muscular atrophy, and severe combined immunodeficiency (SCID).
Suicide Gene Therapy: A safety strategy where therapeutic cells are engineered to express genes that can be activated to kill the cells if adverse effects occur. Herpes simplex virus thymidine kinase (HSV-TK) is commonly used, making cells sensitive to ganciclovir. This provides a "safety switch" for cell therapies and oncolytic virotherapy.
Germline Gene Therapy: Genetic modifications made to reproductive cells (sperm, eggs) or early embryos that would be inherited by future generations. While potentially able to eliminate hereditary diseases permanently, germline editing raises profound ethical concerns and is currently prohibited for human reproductive purposes in most countries due to safety uncertainties and societal implications.
Somatic Gene Therapy: Genetic modifications made to non-reproductive body cells, affecting only the treated individual without hereditary transmission. This ethically less controversial approach is the basis of all currently approved gene therapies and encompasses treatments for inherited disorders, cancer, and acquired diseases.
Oncolytic Virotherapy: A cancer treatment using genetically modified viruses that selectively infect, replicate within, and destroy cancer cells while sparing normal tissue. Oncolytic viruses can also stimulate anti-tumour immune responses. Examples include T-VEC (talimogene laherparepvec) for melanoma and investigational agents targeting various solid tumours.
RNA Interference Therapy: Therapeutic use of small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) to silence disease-causing genes through the cell's natural RNAi machinery. FDA-approved examples include patisiran for hereditary transthyretin amyloidosis and givosiran for acute hepatic porphyria.

Viral Vectors & Systems13

Viral Vector: A virus that has been genetically modified to remove disease-causing genes and incorporate therapeutic genetic cargo. Viral vectors exploit viruses' natural ability to efficiently deliver genetic material into cells. Key modifications ensure safety by preventing viral replication while maintaining high transduction efficiency.
Adenoviral Vector (AdV): A non-integrating viral vector derived from adenoviruses that can transduce both dividing and non-dividing cells with high efficiency. Adenoviral vectors provide transient gene expression, have large cargo capacity (up to 37 kb), and are relatively easy to produce at high titers. However, they elicit strong immune responses limiting repeat administration and long-term expression.
Adeno-Associated Virus (AAV): A small, non-pathogenic parvovirus widely considered the gold standard for gene therapy due to excellent safety profiles, ability to transduce non-dividing cells, and long-term expression from episomal genomes. AAV exists in multiple natural serotypes with different tissue tropisms. Limitations include small cargo capacity (~4.7 kb), pre-existing immunity in populations, and high manufacturing costs.
Lentiviral Vector: A retroviral vector derived from lentiviruses (including HIV-1) capable of integrating into the genome of both dividing and non-dividing cells, providing stable, long-term expression. Lentiviral vectors are essential tools for ex vivo gene therapy, particularly CAR-T cell manufacturing and haematopoietic stem cell therapy. Self-inactivating (SIN) designs enhance safety.
Retroviral Vector: Viral vectors derived from retroviruses (typically murine leukaemia virus) that integrate into host cell genomes, providing permanent gene expression. Unlike lentiviral vectors, traditional retroviral vectors only transduce dividing cells. Integration near oncogenes can cause insertional mutagenesis, a safety concern highlighted by early SCID gene therapy trials.
Herpes Simplex Virus (HSV) Vector: Large DNA virus vectors with substantial cargo capacity (>30 kb) and natural neurotropism, making them attractive for CNS applications. HSV vectors can remain episomal providing long-term expression in neurons, or be engineered as amplicons with minimal viral sequences. Applications include pain management, neurodegenerative diseases, and glioblastoma.
Baculovirus Vector: An insect virus vector with excellent safety for mammalian applications due to lack of human pathogenicity. Baculoviruses can transduce mammalian cells with appropriate modifications, provide large cargo capacity, and enable pseudotyping with other viral envelopes. Used for vaccine production and gene delivery research.
Vaccinia Virus Vector: A poxvirus with large genome and cargo capacity used historically in smallpox vaccination and currently investigated for cancer immunotherapy and vaccine development. Vaccinia's cytoplasmic replication avoids integration risks but limits persistence. It induces strong immune responses useful for vaccination but limiting for gene therapy.
Alphavirus Vector: RNA virus vectors (including Semliki Forest virus and Sindbis virus) providing high-level transient expression, broad tropism, and self-replication capabilities. These vectors are particularly valuable for vaccine development and cancer immunotherapy where transient, potent gene expression is desirable.
Vector Tropism: The natural preference of viral vectors for infecting specific cell types, determined by interactions between viral surface proteins and cellular receptors. Understanding and modifying tropism is crucial for targeted gene delivery. Tropism can be altered through pseudotyping, directed evolution, or rational engineering of viral capsids or envelopes.
Pseudotyping: The process of engineering viral vectors to display envelope proteins from different viruses, thereby altering cell type specificity. For example, VSV-G (vesicular stomatitis virus glycoprotein) pseudotyped lentivirus provides broad tropism and enhanced stability, while other envelopes enable neuron-specific or liver-specific targeting.
Capsid Engineering: Rational design or directed evolution of viral capsid proteins to achieve desired properties including altered tropism, reduced immunogenicity, enhanced transduction efficiency, or ability to cross biological barriers like the blood-brain barrier. AAV capsid variants created through this approach have enabled tissue-specific gene delivery.
Self-Amplifying RNA (saRNA): Viral replicon-based vectors that encode both the therapeutic gene and viral replication machinery, enabling RNA amplification within transfected cells. This provides high protein expression from minimal initial doses. SAMVs are being developed as vaccines and for cancer immunotherapy.

Non-Viral Vectors & Delivery Systems16

Non-Viral Vector: Synthetic or naturally-derived gene delivery systems that avoid the immunogenicity and safety concerns of viral vectors while offering advantages in cargo size, manufacturing scalability, and repeat administration capability. Non-viral vectors include lipid-based systems, polymers, peptides, and inorganic nanoparticles, though they typically achieve lower transfection efficiency than viral vectors.
Liposome: Spherical vesicles composed of one or more lipid bilayers surrounding an aqueous core, mimicking natural cell membrane structure. Liposomes can encapsulate hydrophilic drugs in the core and hydrophobic drugs in the bilayer. Their biocompatibility, versatility, and ability to protect cargo from degradation make them valuable for drug and gene delivery. Doxil (liposomal doxorubicin) was the first FDA-approved nanomedicine.
Lipid Nanoparticle (LNP): Advanced lipid-based delivery systems typically composed of ionisable cationic lipids, phospholipids, cholesterol, and PEGylated lipids. LNPs efficiently encapsulate and deliver nucleic acids, particularly mRNA, through pH-dependent membrane fusion and endosomal escape. The COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) utilise LNP technology, demonstrating clinical viability at unprecedented scale.
Ionisable Lipid: A key LNP component that remains neutral at physiological pH (avoiding toxicity) but becomes positively charged in acidic endosomal compartments (facilitating endosomal escape and nucleic acid release). Examples include DLin-MC3-DMA, SM-102, and ALC-0315. Ionisable lipid structure critically determines LNP performance, biodistribution, and safety.
Cationic Liposome: Positively charged liposomes that electrostatically complex with negatively charged nucleic acids, forming lipoplexes. While effective for gene delivery, permanently cationic lipids can cause toxicity and rapid clearance. Early examples include DOTMA and DOTAP; modern formulations often use ionisable lipids instead.
Solid Lipid Nanoparticle (SLN): Nanocarriers with a solid lipid core at body temperature, providing controlled drug release, physical stability, and protection of labile compounds. SLNs are easier to scale up than liposomes and offer sustained release kinetics useful for chronic disease management.
Nanostructured Lipid Carrier (NLC): An improved version of SLNs using mixtures of solid and liquid lipids, creating imperfect crystal structure with enhanced drug loading capacity, reduced drug expulsion during storage, and modulated release profiles.
Polymeric Nanoparticle: Nanoparticles constructed from biodegradable or non-biodegradable polymers offering tunable properties including size, surface charge, release kinetics, and targeting ligand display. Polymeric systems provide versatility in design and can achieve sustained release, making them valuable for both drug and gene delivery.
PLGA (Poly(lactic-co-glycolic acid)): FDA-approved biodegradable copolymer widely used in drug delivery. PLGA degrades via hydrolysis into lactic acid and glycolic acid (natural metabolites), is biocompatible, and provides controlled release. Properties can be tuned by adjusting lactide:glycolide ratio and molecular weight.
Polyethylenimine (PEI): A cationic polymer that efficiently condenses DNA/RNA and facilitates endosomal escape through the "proton sponge effect" (buffering endosomal acidification, causing osmotic swelling and rupture). While highly efficient for transfection, PEI shows significant cytotoxicity, particularly high molecular weight branched forms. Modified PEIs with reduced toxicity are under development.
Chitosan: A natural cationic polysaccharide derived from chitin with excellent biocompatibility, biodegradability, and mucoadhesive properties. Chitosan can form nanoparticles with nucleic acids and has intrinsic antimicrobial activity. Its positive charge at physiological pH makes it useful for gene delivery, though transfection efficiency is generally lower than synthetic polymers.
Dendrimers: Precisely engineered, highly branched polymeric nanostructures with tree-like architecture, multiple functional surface groups, and internal cavities for drug encapsulation. PAMAM (polyamidoamine) dendrimers are most common for biomedical applications. Their monodisperse size, multivalency, and modifiable surface enable controlled drug release and targeted delivery.
Polymersomes: Vesicles self-assembled from amphiphilic block copolymers, analogous to liposomes but with thicker, tougher membranes providing enhanced stability and cargo retention. Polymersomes can encapsulate hydrophilic and hydrophobic drugs simultaneously and are being explored for delivering proteins, genes, and imaging agents.
Micelles: Colloidal particles (typically 10-100 nm) formed by self-assembly of amphiphilic molecules in aqueous solution, with hydrophobic cores for poorly soluble drug encapsulation and hydrophilic shells for aqueous stability. Polymeric micelles offer passive tumour targeting via EPR effect and have achieved clinical success (Genexol-PM for breast cancer).
Peptide-Based Vectors: Gene delivery systems composed of cationic or amphipathic peptides that condense nucleic acids and facilitate cellular uptake. Peptides offer advantages including biodegradability, low toxicity, and the ability to incorporate functional sequences for targeting, endosomal escape, and nuclear localisation. Examples include poly-L-lysine, histidine-rich peptides, and GALA peptide.
Lipopolyplex: Ternary complexes combining cationic polymers (complexing nucleic acids), cationic lipids (facilitating membrane fusion), and nucleic acids. This hybrid approach aims to combine the advantages of lipoplexes and polyplexes while minimising individual limitations, potentially achieving high transfection efficiency with reduced toxicity.

Inorganic Nanomaterials14

Gold Nanoparticles (AuNPs): Metallic nanoparticles with unique optical properties (surface plasmon resonance), biocompatibility, and ease of functionalisation through gold-thiol chemistry. Applications include drug/gene delivery, imaging, biosensing, photothermal therapy, and diagnostic assays. AuNPs can be synthesised in various shapes (spheres, rods, stars, shells) with different properties.
Silver Nanoparticles (AgNPs): Metallic nanoparticles with potent antimicrobial properties exploited in wound dressings, medical devices, and infection control. Silver ions released from AgNPs disrupt bacterial membranes and cellular functions. However, potential toxicity to mammalian cells requires careful design for therapeutic applications.
Quantum Dots (QDs): Semiconductor nanocrystals (2-10 nm) with quantum confinement effects producing size-tunable fluorescence, high brightness, photostability, and broad excitation spectra. QDs enable multicolor imaging, long-term cell tracking, and sensitive biosensing. Cadmium-based QDs raise toxicity concerns; newer materials include indium phosphide, graphene, and carbon dots.
Carbon Nanotubes (CNTs): Cylindrical carbon allotropes with exceptional mechanical strength, electrical conductivity, and high surface area. Single-walled (SWCNTs) and multi-walled (MWCNTs) variants show promise for drug/gene delivery, biosensing, tissue engineering scaffolds, and cancer photothermal therapy. However, biopersistence and potential toxicity require careful surface modification and evaluation.
Graphene and Graphene Oxide: Two-dimensional carbon nanomaterials with large surface area, mechanical strength, and unique electronic properties. Graphene oxide's hydrophilicity, functional groups, and biocompatibility enable drug/gene loading and cellular delivery. Applications include biosensors, tissue engineering, neural interfaces, and photothermal/photodynamic therapy.
Mesoporous Silica Nanoparticles (MSNs): Porous silica structures with highly ordered, tunable pore sizes (2-50 nm), large surface area (>900 m²/g), excellent biocompatibility, and chemical stability. MSNs enable high drug loading, controlled release through pore modification or gating, and multi-functionality through surface modification. They can deliver small molecules, proteins, and nucleic acids.
Magnetic Nanoparticles: Iron oxide (magnetite or maghemite) nanoparticles with superparamagnetic properties enabling magnetic guidance, MRI contrast enhancement, and magnetic hyperthermia for cancer treatment. Surface modification with polymers or targeting ligands improves biocompatibility and specificity. Clinical applications include MRI contrast agents (Feraheme, Resovist) and magnetic hyperthermia.
Upconversion Nanoparticles (UCNPs): Lanthanide-doped nanocrystals that convert near-infrared light to visible/UV light through anti-Stokes emission. UCNPs enable deep tissue imaging with minimal autofluorescence background, photodynamic therapy activation at depth, and optogenetic control. Their unique optical properties overcome limitations of conventional fluorophores.
Calcium Phosphate Nanoparticles: Biocompatible, biodegradable nanoparticles composed of materials similar to bone mineral (hydroxyapatite). These pH-sensitive systems can deliver genes and drugs with good biocompatibility, though they tend to aggregate and show variable transfection efficiency. Surface coating with polymers or lipids improves stability.
Cerium Oxide Nanoparticles (Nanoceria): Redox-active nanoparticles with antioxidant properties that scavenge reactive oxygen species. Nanoceria show promise for treating oxidative stress-related diseases including neurodegenerative disorders, ischaemia-reperfusion injury, and radiation damage. The Ce³⁺/Ce⁴⁺ redox cycle provides catalytic antioxidant activity.
Prussian Blue Nanoparticles: Iron-based coordination polymer nanoparticles with FDA approval for treating radioactive caesium and thallium poisoning. Beyond detoxification, these nanoparticles show promise for photothermal therapy, photoacoustic imaging, and drug delivery due to their biocompatibility and NIR absorption properties.
Silica Nanoparticles (Non-porous): Solid silica nanospheres offering excellent biocompatibility, facile surface modification, optical properties, and monodisperse size control. Applications include drug delivery, imaging, diagnostics, and as building blocks for more complex nanostructures. Cornell dots (fluorescent silica nanoparticles) are in clinical trials for cancer imaging.
Layered Double Hydroxides (LDHs): Anionic clays with positively charged hydroxide layers and exchangeable interlayer anions. LDHs can intercalate and deliver negatively charged drugs and genes, provide pH-responsive release, and show excellent biocompatibility. Their unique structure enables protection of biomolecules and sustained release.
Metal-Organic Frameworks (MOFs): Crystalline porous materials composed of metal ions/clusters coordinated to organic linkers, offering ultra-high surface area, tunable pore size, and versatile functionality. Biodegradable MOFs (e.g., iron-based MIL-100/101) show promise for drug delivery, imaging, and gas therapy with controlled cargo release.

Nanomedicine Concepts & Applications15

Nanomedicine: An interdisciplinary field applying nanotechnology principles and nanomaterials to medicine for prevention, diagnosis, monitoring, and treatment of diseases. Nanomedicine exploits the unique properties of materials at the nanoscale (1-1000 nm) where quantum effects and high surface-to-volume ratios create novel biological interactions impossible with bulk materials.
Nanocarrier: Any nanoscale delivery system designed to transport therapeutic, diagnostic, or theranostic agents to specific locations in the body. Nanocarriers protect cargo from degradation, improve pharmacokinetics, reduce off-target effects, enable controlled release, and can overcome biological barriers. The ideal nanocarrier is biocompatible, biodegradable, scalable, and precisely targetable.
Theranostics: The integration of diagnostics and therapeutics in a single platform, enabling simultaneous disease detection, treatment monitoring, and therapy delivery. Nanotheranostic agents might combine MRI contrast agents with chemotherapy drugs, enabling real-time visualisation of drug delivery and therapeutic response. This paradigm enables personalised, precision medicine approaches.
Stimuli-Responsive Nanoparticles: "Smart" delivery systems that release cargo in response to specific triggers including pH changes (tumour acidity, endosomal acidification), temperature (hyperthermia, body heat), enzymes (tumour-specific proteases), light (photodynamic therapy activation), ultrasound, magnetic fields, or redox potential. This enables controlled, on-demand drug release at disease sites while minimising systemic exposure.
Photothermal Therapy (PTT): Cancer treatment using light-absorbing nanomaterials (gold nanostructures, carbon nanotubes, nanoceria) that convert absorbed light (typically near-infrared) into heat, raising local temperature to kill cancer cells. PTT offers spatial and temporal control, minimal invasiveness, and can be combined with chemotherapy or immunotherapy for synergistic effects.
Photodynamic Therapy (PDT): Treatment using photosensitizer drugs that generate reactive oxygen species upon light activation, killing cancer cells or pathogens. Nanocarriers improve photosensitizer delivery, solubility, and tumour accumulation. PDT is FDA-approved for certain cancers and age-related macular degeneration, with advantages including minimal invasiveness and repeatability.
Magnetic Hyperthermia: Cancer therapy where magnetic nanoparticles are accumulated in tumours and exposed to alternating magnetic fields, generating heat that kills cancer cells. This approach offers deep tissue penetration (unlike light-based therapies) and can be precisely targeted. Clinical trials show promise for glioblastoma and prostate cancer.
Multimodal Imaging Nanoparticles: Nanoplatforms incorporating multiple imaging modalities (MRI, PET, optical, ultrasound) to overcome individual technique limitations. For example, combining high-resolution MRI with sensitive PET imaging enables both anatomical detail and metabolic information, improving diagnostic accuracy and treatment planning.
Nanozymes: Nanomaterials with enzyme-like catalytic activities that overcome natural enzyme limitations including instability, high cost, and difficulty tuning properties. Examples include cerium oxide (antioxidant), iron oxide (peroxidase-like), and gold nanoparticles (oxidase-like). Applications span biosensing, therapeutics, and environmental remediation.
Nanoemulsions: Submicron emulsions (20-500 nm) with superior kinetic stability, optical clarity, and large interfacial area compared to conventional emulsions. Nanoemulsions efficiently solubilise lipophilic drugs, improve bioavailability, and can deliver both drugs and nutrients. Examples include propofol formulations and parenteral nutrition.
Nanovaccines: Vaccine formulations using nanoparticles as antigen carriers and/or adjuvants to enhance immune responses. Nanoparticles can protect antigens from degradation, facilitate uptake by antigen-presenting cells, provide sustained release, and co-deliver immunostimulatory molecules. COVID-19 mRNA vaccines represent a revolutionary success of nanovaccine technology.
Immunotherapy Nanoparticles: Delivery systems for cancer immunotherapy agents including immune checkpoint inhibitors, cancer vaccines, immunostimulatory adjuvants, and adoptive cell therapy support. Nanoparticles can enhance immune cell activation, reduce systemic toxicity, improve tumour penetration, and reprogram the immunosuppressive tumour microenvironment.
Regenerative Nanomedicine: Application of nanomaterials in tissue engineering and regenerative medicine including nanofiber scaffolds mimicking extracellular matrix, nanoparticle-mediated growth factor delivery, and nanomaterial-enhanced stem cell therapies. Nanomaterials provide appropriate mechanical and biochemical cues for tissue regeneration.
Nanobiologics: Biological therapeutics delivered or enhanced by nanotechnology including proteins, antibodies, nucleic acids, and cellular products. Nanocarriers protect biologics from degradation, extend circulation time, enable oral delivery of typically injectable drugs, and improve tissue penetration.
Exosome-Mimetic Nanovesicles: Synthetic or semi-synthetic nanoparticles designed to replicate exosome structure and function for drug/gene delivery. These avoid the heterogeneity and scalability challenges of natural exosomes while maintaining biocompatibility and ability to cross biological barriers.

Cellular Uptake & Intracellular Trafficking15

Endocytosis: The fundamental cellular process by which cells internalise extracellular materials by membrane invagination and vesicle formation. Different endocytic pathways (clathrin-mediated, caveolae-mediated, macropinocytosis, phagocytosis) have distinct mechanisms, cargo selectivity, and intracellular fates. Understanding these pathways is crucial for designing effective drug delivery systems.
Clathrin-Mediated Endocytosis (CME): The most common and well-characterised endocytic pathway involving clathrin-coated pits that form vesicles (100-150 nm) around receptor-bound cargo. CME is receptor-mediated, enabling targeted delivery via ligand-functionalised nanoparticles. Internalised vesicles traffic to early endosomes, then late endosomes/lysosomes where cargo typically degrades unless it escapes.
Caveolae-Mediated Endocytosis: Uptake via small (50-80 nm) flask-shaped plasma membrane invaginations enriched in caveolin proteins and cholesterol. This pathway may avoid lysosomal degradation, making it attractive for drug delivery, though it's slower and less efficient than CME. Caveolae involvement in signalling and lipid regulation makes this pathway relevant for various diseases.
Macropinocytosis: Non-selective uptake of large volumes of extracellular fluid and solutes through actin-driven membrane ruffling, forming large vesicles (0.5-5 μm macropinosomes). Cancer cells often show enhanced macropinocytosis for nutrient scavenging. This pathway enables uptake of large particles and is exploited for albumin-bound drug delivery.
Phagocytosis: Uptake of large particles (>0.5 μm) by specialised cells (macrophages, neutrophils, dendritic cells) for pathogen clearance and antigen presentation. While phagocytosis typically leads to cargo destruction, it's exploited for vaccine delivery, cancer immunotherapy, and treating phagocytic cell diseases. Nanoparticle size, shape, and surface properties influence phagocytic uptake.
Receptor-Mediated Endocytosis: Targeted cellular uptake initiated by ligand binding to specific cell surface receptors. This enables selective delivery to cells expressing particular receptors (e.g., folate receptors on cancer cells, transferrin receptors on rapidly dividing cells). Receptor-mediated pathways typically lead to recycling endosomes or lysosomes.
Endosomal Escape: The critical and often rate-limiting step where delivered materials must exit endosomal/lysosomal compartments to reach cytoplasm and avoid degradation. Strategies include pH-responsive materials causing membrane disruption, fusogenic peptides, photochemical internalisation, and proton sponge effect. Inefficient endosomal escape is a major limitation of non-viral gene delivery.
Proton Sponge Effect: A mechanism of endosomal escape where polymers with high buffering capacity (like polyethylenimine) sequester protons pumped into endosomes, preventing acidification. Continued proton pumping causes chloride and water influx, osmotic swelling, and eventual endosomal membrane rupture, releasing contents into cytoplasm. While widely cited, the exact contribution of this mechanism versus direct membrane disruption remains debated.
Lysosomal Degradation: The breakdown of internalised materials in lysosomes, acidic organelles (pH 4.5-5) containing hydrolytic enzymes. Most endocytosed nanoparticles traffic to lysosomes where they and their cargo face degradation. Avoiding or delaying lysosomal trafficking is essential for successful intracellular delivery of proteins, nucleic acids, and sensitive drugs.
Early Endosome: The first sorting station for endocytosed materials (pH ~6.0-6.5) where cargo is sorted for recycling to the plasma membrane, transport to the Golgi, or progression to late endosomes. Early endosomes have tubular and vesicular domains with distinct fates. Some pH-sensitive nanoparticles are designed to disrupt membranes at early endosome pH.
Late Endosome: Acidic compartments (pH ~5.0-6.0) representing maturation from early endosomes, characterised by intraluminal vesicles and progression toward lysosomal fusion. Late endosomes contain acid hydrolases and are the last opportunity for cargo escape before full lysosomal degradation. Materials can also be sorted here for secretion via exosomes.
Cytoplasmic Trafficking: Movement of delivered materials through the cytoplasm toward target organelles, particularly the nucleus for gene delivery. This involves diffusion (for small molecules), microtubule-based transport (for larger particles), and interaction with cytoplasmic machinery. Cytoplasmic barriers can significantly impede delivery efficiency.
Nuclear Entry: Transport across the nuclear envelope, essential for DNA-based therapeutics that require nuclear localisation for efficacy. Small molecules (<40 kDa) can diffuse through nuclear pores, but plasmid DNA and large complexes require active transport via nuclear localisation signals (NLS) or nuclear pore enlargement during mitosis.
Nuclear Localisation Signal (NLS): Amino acid sequences (typically enriched in basic residues like lysine and arginine) that direct proteins to the nucleus via recognition by importin proteins. Incorporating NLS peptides into gene delivery vectors enhances nuclear import of DNA, improving transfection efficiency particularly in non-dividing cells where mitotic nuclear envelope breakdown doesn't occur.
Autophagy: A cellular degradation pathway where cytoplasmic materials are sequestered in double-membrane autophagosomes and delivered to lysosomes. Nanoparticles can trigger or be degraded by autophagy, affecting therapeutic efficacy. Understanding and manipulating autophagy pathways may enhance delivery or enable autophagy-targeted therapies for neurodegenerative diseases and cancer.

Biological Barriers & Challenges14

Blood-Brain Barrier (BBB): A highly selective semipermeable barrier formed by brain endothelial cells with tight junctions, limiting passage of substances from blood to brain parenchyma. The BBB protects the CNS but prevents delivery of most therapeutic agents. Strategies to overcome the BBB include receptor-mediated transcytosis, cell-penetrating peptides, focused ultrasound, and engineered viral capsids.
Blood-Tumour Barrier (BTB): A selective barrier in brain tumours resulting from abnormal but still restrictive vasculature. While more permeable than normal BBB, BTB still limits therapeutic delivery, particularly in glioblastoma where the barrier is heterogeneous. Convection-enhanced delivery and focused ultrasound can temporarily disrupt BTB for enhanced drug delivery.
Reticuloendothelial System (RES) / Mononuclear Phagocyte System (MPS): Network of phagocytic cells in liver (Kupffer cells), spleen, lymph nodes, and bone marrow that rapidly clear foreign particles from circulation. RES clearance is a major challenge for nanoparticle drug delivery, severely limiting circulation time and tumour accumulation. Surface modification (PEGylation, self-peptides) reduces RES uptake.
Opsonisation: The coating of foreign particles with blood plasma proteins (opsonins) including immunoglobulins and complement components that mark them for recognition and phagocytosis by immune cells. Opsonisation is the primary mechanism of rapid nanoparticle clearance. Designing "stealth" nanoparticles that resist opsonisation is crucial for achieving adequate circulation time.
Protein Corona: The dynamic layer of proteins that adsorb onto nanoparticle surfaces immediately upon exposure to biological fluids, fundamentally altering their biological identity. Protein corona composition affects cellular uptake, biodistribution, toxicity, and targeting ability, often overriding designed surface properties. Understanding and controlling corona formation is essential for predictable nanoparticle behaviour.
Mucus Barrier: Viscoelastic gel layers protecting epithelial surfaces in lungs, gastrointestinal tract, vaginal tract, and eyes. Mucus traps and clears pathogens and particles, presenting a significant obstacle for drug delivery across mucosal surfaces. Strategies include mucoadhesive formulations (prolonging residence) or mucopenetrating nanoparticles (reaching epithelium).
Extracellular Matrix (ECM): Complex network of proteins, glycoproteins, and polysaccharides providing structural support to tissues and regulating cell behaviour. Dense ECM in tumours and fibrotic tissues impedes nanoparticle penetration and distribution. Matrix metalloproteinases and hyaluronidase can be co-delivered to degrade ECM and enhance penetration.
Tumour Microenvironment (TME): The complex ecosystem surrounding tumour cells including blood vessels, immune cells, fibroblasts, ECM, and distinct biochemical features (hypoxia, acidosis, elevated interstitial pressure). TME presents multiple barriers to drug delivery but also offers targeting opportunities through pH-responsive systems, hypoxia-activated prodrugs, and immunomodulation.
Interstitial Fluid Pressure (IFP): Elevated pressure in tumour interstitium (up to 10-40 mmHg vs. ~0 mmHg in normal tissue) resulting from abnormal vasculature, poor lymphatic drainage, and dense ECM. High IFP impedes convective transport of therapeutics from blood to deep tumour regions. Normalising tumour vasculature or reducing IFP can improve drug delivery.
Immunogenicity: The capacity of a substance to provoke immune responses including antibody production, complement activation, and cellular immunity. Immunogenicity can cause hypersensitivity reactions, reduce therapeutic efficacy through neutralising antibodies, and prevent repeat dosing. PEGylation reduces immunogenicity, though anti-PEG antibodies are increasingly recognised.
Complement Activation: Triggering of the complement cascade by nanoparticles, leading to opsonisation, inflammation, and potentially life-threatening anaphylaxis (complement activation-related pseudoallergy, CARPA). Surface properties including charge, hydrophobicity, and specific functional groups influence complement activation. Careful design and preclinical testing are essential.
Glomerular Filtration: Kidney-mediated clearance of small nanoparticles and molecules (<5-6 nm) through glomerular capillaries. This limits circulation time of very small nanoparticles and causes renal accumulation potentially leading to toxicity. Particles >6 nm typically avoid filtration, balancing the need for small size (EPR effect) with adequate circulation time.
Intestinal Barrier: Multilayered defence including digestive enzymes, low pH, mucus, tight junction-connected epithelial cells, and gut immune system that limits oral drug absorption. Nanocarriers can protect drugs from degradation, enhance epithelial permeability, and enable oral delivery of biologics (proteins, nucleic acids) that normally require injection.
Placental Barrier: Selective barrier protecting the fetus from maternal blood-borne substances while allowing nutrient and waste exchange. Most nanoparticles don't cross the placenta, though small size and specific surface properties may enable transfer. Understanding placental transport is crucial for pregnancy drug delivery and assessing developmental toxicity risks.

Targeting & Biodistribution19

Active Targeting: Decoration of nanocarriers with ligands (antibodies, peptides, aptamers, small molecules) that bind specific receptors overexpressed on target cells, enhancing selective accumulation and cellular uptake. Active targeting improves specificity but requires sufficient vascular delivery (often via passive targeting) to reach the target site. Successful examples include folate, transferrin, and antibody-targeted systems.
Passive Targeting: Accumulation of nanoparticles at disease sites due to intrinsic physicochemical properties and pathophysiological features rather than specific ligand-receptor interactions. The EPR effect in tumours represents the classic passive targeting mechanism. Particle size, surface charge, shape, and surface modification determine passive distribution patterns.
EPR Effect (Enhanced Permeability and Retention): Phenomenon where macromolecules and nanoparticles (typically 10-200 nm) preferentially accumulate in tumours due to leaky vasculature (enhanced permeability) and impaired lymphatic drainage (enhanced retention). First described by Maeda, EPR provides the foundation for nanomedicine cancer therapy. However, EPR extent varies significantly across tumour types and patients.
EPR Effect Controversy: Growing recognition that EPR-based passive targeting may be less universal and reliable than initially believed, particularly in human patients vs. mouse models. Many clinical nanomedicine trials have shown disappointing results, with median tumour accumulation often <1% of injected dose. This has sparked debate about EPR's clinical relevance and need for improved targeting strategies.
Ligand-Receptor Targeting: Active targeting approach using ligands (natural molecules, peptides, antibodies) that bind specific cell surface receptors overexpressed on diseased cells. Examples include folate receptors in cancer, transferrin receptors in brain, VEGF receptors in angiogenic vessels, and integrins in cancer/inflammation. Success requires receptor selectivity, expression level, and internalisation.
Antibody-Drug Conjugates (ADCs): Therapeutic antibodies conjugated to cytotoxic drugs via chemical linkers, combining antibody specificity with potent drug activity. ADCs represent a form of nanoscale targeted delivery with multiple FDA approvals (Kadcyla, Adcetris). Challenges include linker stability, drug release mechanisms, and resistance development.
Aptamer-Targeted Delivery: Using nucleic acid aptamers (single-stranded DNA/RNA sequences) that fold into 3D structures recognising specific targets with antibody-like affinity and specificity. Aptamers offer advantages including small size, synthetic production, low immunogenicity, and chemical modifiability. They can target extracellular proteins, cell surface receptors, and tumour microenvironment components.
Peptide-Mediated Targeting: Using short peptide sequences for specific cell/tissue targeting, discovered through phage display, rational design, or natural ligand identification. Examples include RGD peptides (integrin targeting), iRGD (tumour-penetrating), and organ-specific peptides from in vivo phage display. Peptides offer advantages including small size, low immunogenicity, and ease of synthesis.
Dual/Multi-Targeting: Incorporating multiple targeting ligands on single nanoparticles to improve specificity, overcome heterogeneity, or sequentially target different cell types/compartments. Examples include tumour vasculature + cancer cell targeting, or cancer cell + immune cell targeting for combination immunotherapy. Multi-targeting can enhance efficacy but increases complexity.
Stimuli-Triggered Targeting: Systems where targeting capability is activated by disease-specific stimuli. Examples include proteolytically activated cell-penetrating peptides (activated by tumour enzymes) and pH-low insertion peptides (activating in acidic tumour environment). This "smart" targeting reduces off-target effects while maintaining high specificity.
Pretargeting Strategy: Two-step approach where targeting agents (e.g., antibodies) are first administered to bind target cells, followed by delivery of therapeutic-loaded nanoparticles that recognise the targeting agent via complementary interactions (biotin-avidin, antibody-antigen). This separates slow targeting from fast clearance, potentially improving tumour accumulation.
Pharmacokinetics: Study of drug absorption, distribution, metabolism, and excretion (ADME) over time, described by parameters including half-life, clearance, volume of distribution, and bioavailability. Nanoparticle pharmacokinetics differ dramatically from free drugs, influenced by size, surface properties, shape, and composition. Understanding PK is essential for dosing regimen design.
Biodistribution: The spatial and temporal pattern of therapeutic distribution throughout the body following administration. Nanoparticles typically accumulate in liver and spleen (RES organs) with variable amounts reaching target tissues. Quantifying biodistribution using radiolabeling, fluorescence, or mass spectrometry is crucial for understanding efficacy and toxicity.
Circulation Half-Life: Time required for blood plasma concentration to decrease by 50%, determining how long therapeutics remain available for tissue accumulation. Most unmodified nanoparticles show rapid clearance (minutes); PEGylation and other modifications extend half-life to hours or days, dramatically improving delivery efficiency.
PEGylation: Covalent attachment of polyethylene glycol (PEG) chains to drug carriers, creating a hydrophilic layer that reduces protein adsorption, immune recognition, and RES clearance while extending circulation time. PEGylation has enabled numerous successful nanomedicines but faces challenges including anti-PEG antibodies and accelerated blood clearance (ABC) phenomenon upon repeated dosing.
Accelerated Blood Clearance (ABC): Phenomenon where repeated administration of PEGylated formulations leads to rapid clearance of subsequent doses due to anti-PEG IgM antibodies. ABC compromises efficacy and represents a significant concern for chronic therapies requiring repeated dosing. Alternative polymer coatings (zwitterionic, polysarcosine) are being developed.
Zwitterionic Surface Modification: Using materials with both positive and negative charges (overall neutral) like phosphorylcholine or carboxybetaine to create ultra-low-fouling surfaces resisting protein adsorption. Zwitterionic coatings show promise as PEG alternatives for prolonging circulation and reducing immunogenicity without triggering ABC phenomenon.
Biomimetic Approach: Coating nanoparticles with natural cell membranes (red blood cells, platelets, cancer cells, immune cells) or membrane proteins (CD47 "don't eat me" signal) to evade immune clearance and achieve prolonged circulation or specific targeting. This approach exploits natural biological camouflage mechanisms.
Organ-Specific Delivery: Designing systems that preferentially accumulate in specific organs based on intrinsic trafficking or targeted modifications. Examples include lipid nanoparticles for liver (naturally hepatotropic), lung targeting via inhalation or surface modification, and brain targeting via receptor-mediated transcytosis. Applications range from gene therapy to vaccination.

Characterisation & Analysis22

Dynamic Light Scattering (DLS): Technique measuring particle size and size distribution by analysing intensity fluctuations of scattered light caused by Brownian motion. DLS provides rapid, non-destructive size analysis for nanoparticles in solution (typically 1-1000 nm range). Reported as hydrodynamic diameter and polydispersity index (PDI), DLS is essential for nanoparticle characterisation though it's less accurate for polydisperse or non-spherical samples.
Zeta Potential: The electrical potential at the particle surface/solution interface (slipping plane), reflecting surface charge. Measured by electrophoretic light scattering, zeta potential indicates colloidal stability (|ζ| > 30 mV generally stable), predicts cellular interactions (cationic particles internalise better but are more toxic), and confirms surface modification success. Biological fluids significantly affect zeta potential through protein adsorption.
Transmission Electron Microscopy (TEM): High-resolution imaging technique using electron beams to visualise nanoparticle morphology, size, structure, and crystallinity at nanometer or atomic resolution. TEM provides direct visualisation confirming DLS results but requires sample preparation (staining, drying) that may induce artifacts. Cryo-TEM preserves hydrated state for more accurate representation.
Scanning Electron Microscopy (SEM): Imaging technique scanning sample surfaces with focused electron beams to produce detailed topographical images. SEM offers excellent depth of field and is useful for surface morphology, though resolution is lower than TEM. Sample preparation is simpler, and newer environmental SEM can image hydrated samples.
Atomic Force Microscopy (AFM): Scanning probe technique that maps surface topography by measuring forces between a sharp probe and sample surface at nanometer resolution. AFM can image nanoparticles in native environment (including liquid), measure mechanical properties, and provide 3D surface information without requiring vacuum or conductive coating.
Hydrodynamic Diameter: The effective diameter of a particle in solution including the particle core plus surface hydration layer and any associated molecules, determined by DLS. Hydrodynamic diameter is typically larger than core diameter measured by TEM and better predicts in vivo behaviour. It varies with ionic strength and pH.
Polydispersity Index (PDI): Dimensionless measure of size distribution width from DLS, ranging from 0 (perfectly monodisperse) to 1 (highly polydisperse). PDI < 0.1 indicates monodisperse samples; 0.1-0.4 is moderately monodisperse; >0.4 suggests polydisperse or multimodal distribution. Low PDI is generally desirable for consistent biological performance and regulatory acceptance.
Encapsulation Efficiency (EE): The percentage of drug/gene initially used that successfully incorporates into nanocarriers, calculated as (encapsulated amount / initial amount) × 100%. High EE (>80%) is desirable for cost-effectiveness and predictable dosing. EE depends on formulation method, drug-carrier interactions, and physicochemical properties.
Loading Capacity (LC): The amount of therapeutic agent per unit weight of carrier, expressed as weight percentage: (drug weight / total formulation weight) × 100%. High loading capacity reduces the carrier burden delivered to patients. LC is limited by drug-carrier compatibility, physicochemical constraints, and maintaining nanoparticle properties.
Drug Release Kinetics: The temporal pattern of drug release from carriers, characterised by in vitro dissolution testing under physiological conditions. Release profiles include burst release (initial rapid release), sustained release (prolonged steady release), or triggered release (stimuli-responsive). Mathematical modelling (zero-order, first-order, Higuchi, Korsmeyer-Peppas) describes release mechanisms.
X-Ray Diffraction (XRD): Analytical technique using X-ray scattering to determine crystal structure, crystallinity, and phase composition of materials. XRD confirms nanoparticle crystallinity vs. amorphous nature, identifies crystal polymorphs affecting stability and dissolution, and can estimate crystallite size via Scherrer equation.
Fourier Transform Infrared Spectroscopy (FTIR): Technique measuring infrared absorption to identify functional groups and chemical bonds in materials. FTIR confirms successful surface modification, drug-polymer interactions, and chemical stability. It's non-destructive, requires minimal sample, and provides molecular fingerprints for quality control.
Differential Scanning Calorimetry (DSC): Thermal analysis measuring heat flow during temperature changes to characterise phase transitions, melting points, glass transitions, and crystallinity. DSC assesses drug-excipient compatibility, drug state (crystalline vs. amorphous), and formulation stability, crucial for developing robust nanoformulations.
Thermogravimetric Analysis (TGA): Technique measuring mass change as a function of temperature to determine composition, thermal stability, and degradation patterns. TGA quantifies organic vs. inorganic components in hybrid nanoparticles, confirms PEG grafting density, and assesses storage stability.
Fluorescence Spectroscopy: Optical technique measuring emitted fluorescence from molecules excited by specific wavelengths. Applications include quantifying fluorescently-labelled drugs/genes, studying nanoparticle-cell interactions via flow cytometry or microscopy, and assessing encapsulation efficiency. Time-resolved fluorescence provides information on molecular environments.
UV-Visible Spectroscopy: Analytical technique measuring light absorption in UV-visible range to quantify drug concentration, characterise nanoparticle optical properties (surface plasmon resonance in gold nanoparticles), and assess colloidal stability. Simple, rapid, and non-destructive, UV-Vis is standard for quality control.
Nuclear Magnetic Resonance (NMR) Spectroscopy: Powerful analytical technique exploiting magnetic properties of nuclei to determine molecular structure, dynamics, and interactions. NMR confirms drug encapsulation within carriers, characterises polymer structure, studies drug-carrier interactions, and can probe nanoparticle internal organisation.
Mass Spectrometry: Analytical technique measuring mass-to-charge ratios to identify and quantify molecules. Coupled with separation techniques (LC-MS, GC-MS), mass spectrometry enables precise drug quantification in biological samples for pharmacokinetic studies, identifies protein corona composition, and characterises polymer degradation products.
Flow Cytometry: Technique analysing physical and chemical properties of individual cells or particles passing through laser beams. Flow cytometry quantifies cellular uptake of fluorescent nanoparticles, measures transfection efficiency, assesses cell viability and apoptosis, and enables high-throughput screening of formulations. Imaging flow cytometry combines this with morphological analysis.
Confocal Laser Scanning Microscopy (CLSM): Advanced fluorescence microscopy technique using pinhole apertures to eliminate out-of-focus light, enabling optical sectioning and 3D reconstruction. CLSM visualises nanoparticle cellular uptake, intracellular localisation, co-localisation with organelles, and tissue distribution with superior resolution compared to widefield microscopy.
Cryo-Electron Microscopy (Cryo-EM): TEM performed on vitrified (flash-frozen) samples, preserving native hydrated structure without fixation or staining artifacts. Recent resolution revolution enables near-atomic structure determination of proteins, viruses, and nanoparticle-biomolecule complexes. Cryo-EM is transforming structural biology and nanomedicine characterisation.
Small Angle X-ray Scattering (SAXS): Technique analysing X-ray scattering at small angles to characterise nanoparticle size, shape, internal structure, and organisation in solution. SAXS provides ensemble-averaged structural information complementing electron microscopy, useful for studying lipid nanoparticles, polymeric micelles, and self-assembled systems.

Safety & Toxicology17

Biocompatibility: The ability of materials to perform their desired function with appropriate host response without causing unacceptable adverse effects. Biocompatibility encompasses cytotoxicity, genotoxicity, immunotoxicity, haemocompatibility, and chronic toxicity. ISO 10993 standards guide biocompatibility testing for medical devices including nanomaterials.
Cytotoxicity: Toxicity to cells, typically assessed by measuring cell viability, proliferation, or membrane integrity after exposure to nanomaterials. Common assays include MTT, MTS, WST, LDH release, and live/dead staining. Cytotoxicity depends on nanoparticle composition, dose, exposure time, cell type, and often correlates with cellular uptake and surface charge.
Genotoxicity: Damage to genetic material that can cause mutations and potentially cancer. Nanoparticles may induce genotoxicity through reactive oxygen species, direct DNA interaction, or interfering with cellular machinery. Assessment includes Ames test, comet assay, micronucleus test, and chromosomal aberration analysis, required for regulatory approval.
Haemolysis: Rupture of red blood cells releasing haemoglobin, a critical safety concern for intravenously administered nanomedicines. Haemolysis can result from membrane disruption by cationic or hydrophobic nanoparticles. ISO 10993-4 requires haemolysis <5% for blood-contacting materials. Haemolysis testing is standard for preclinical evaluation.
Haemocompatibility: Compatibility with blood components including red cells, white cells, platelets, and coagulation cascade. Beyond haemolysis, assessment includes platelet activation, coagulation (PT, aPTT), complement activation, and effects on blood cells. Poor haemocompatibility can cause thrombosis, embolism, or haemorrhage.
Reactive Oxygen Species (ROS): Chemically reactive molecules containing oxygen (superoxide, hydrogen peroxide, hydroxyl radicals) that can damage DNA, proteins, and lipids. Many nanoparticles generate ROS through surface reactions or mitochondrial dysfunction, contributing to toxicity. However, controlled ROS generation is exploited therapeutically in photodynamic therapy and cancer treatment.
Oxidative Stress: Imbalance between ROS production and antioxidant defences, causing cellular damage. Nanoparticle-induced oxidative stress can trigger inflammation, apoptosis, and pathological changes. Antioxidant coatings or co-administration may mitigate oxidative stress while maintaining therapeutic effects.
Inflammation: Immune response to nanoparticles involving cytokine release, immune cell recruitment, and tissue changes. While acute inflammation may resolve, chronic inflammation can cause fibrosis and organ damage. Assessing inflammatory markers (TNF-α, IL-6, IL-1β) and histopathology is essential for safety evaluation.
Immunotoxicity: Adverse effects on immune system function including immunosuppression (reduced defence against infections/cancer) or immunostimulation (hypersensitivity, autoimmunity). Nanomaterials can affect immune cells, cytokine profiles, and humoral/cellular immunity. Comprehensive immunotoxicity assessment is increasingly required for regulatory approval.
Protein Corona Formation: The immediate and dynamic adsorption of blood proteins onto nanoparticle surfaces in vivo, creating a biomolecular layer that becomes the biological identity seen by cells. Corona composition affects cellular uptake, biodistribution, toxicity, and immune responses, often overriding designed surface properties. Understanding and controlling corona formation is crucial for predicting nanoparticle behaviour.
Nano-Bio Interface: The complex interactions occurring at the interface between nanomaterials and biological systems at molecular, cellular, and tissue levels. These interactions determine nanoparticle fate, efficacy, and toxicity. Nano-bio interface research investigates how nanomaterial properties (size, shape, charge, surface chemistry) influence biological responses.
Biopersistence: The duration that nanomaterials remain in the body without degradation or excretion. Non-degradable nanomaterials (gold, carbon nanotubes, some silica) may accumulate in organs causing long-term toxicity concerns. Biodegradable systems (lipids, polymers) are preferred for reducing biopersistence and enabling clearance.
Organ Toxicity: Damage to specific organs, with common targets including liver (hepatotoxicity), kidneys (nephrotoxicity), lungs (pulmonary toxicity), and heart (cardiotoxicity). Organ-specific accumulation patterns and sensitivity determine toxicity profiles. Comprehensive toxicology studies assess multiple organs through biochemistry, histopathology, and functional tests.
Developmental and Reproductive Toxicity (DART): Adverse effects on sexual function, fertility, or development from conception through puberty. DART studies assess effects on gametes, embryo-fetal development, and postnatal development. Understanding whether nanoparticles cross placental barrier and affect fetuses is crucial for clinical translation.
Carcinogenicity: Potential to cause cancer through mechanisms including genotoxicity, chronic inflammation, or oxidative stress. While long-term carcinogenicity studies (2+ years in rodents) are resource-intensive, they're necessary for chronically administered nanomedicines. Some nanomaterials (asbestos-like fibres) show carcinogenic potential while others are considered safe.
Alternative Testing Methods: In vitro and in silico approaches reducing animal use per 3Rs principles (Replace, Reduce, Refine). Examples include organ-on-chip systems, 3D tissue models, predictive computational modelling, and high-throughput screening. Regulatory agencies increasingly accept validated alternative methods for safety assessment.
Good Laboratory Practice (GLP): Quality standards ensuring reliability and integrity of preclinical safety studies for regulatory submission. GLP encompasses study design, documentation, standard operating procedures, quality assurance, and data management. Non-GLP exploratory studies guide development, while GLP studies support regulatory filings.

Regulatory & Clinical Translation28

Good Manufacturing Practice (GMP): Quality assurance systems ensuring pharmaceutical products are consistently produced and controlled according to quality standards appropriate for their intended use. GMP covers premises, equipment, personnel, documentation, and quality control. Clinical-grade nanomedicines require GMP manufacturing, with specific challenges for nanoformulation complexity and characterisation.
Current Good Manufacturing Practice (cGMP): FDA regulations (21 CFR Parts 210-211) specifying GMP requirements for drug manufacturing including documentation, validation, quality control, and facility standards. cGMP compliance is mandatory for clinical trials and commercial products, ensuring safety, efficacy, and quality consistency.
Investigational New Drug (IND): FDA application required before clinical testing of new drugs in humans, including preclinical safety data, manufacturing information, and clinical protocol. For nanomedicines, IND submissions must address nanospecific characterisation, toxicology, and quality control. IND approval enables Phase 1 trials.
New Drug Application (NDA): Comprehensive FDA submission requesting approval to market a drug, including all preclinical and clinical data, manufacturing information, and proposed labelling. Nanomedicine NDAs face enhanced scrutiny regarding characterisation, manufacturing consistency, and long-term safety. Approval takes ~10 months under standard review.
Biologics License Application (BLA): FDA application for approval of biological products including gene therapies, vaccines, and cell therapies. BLA requirements are similar to NDA but emphasise biological manufacturing complexities, facility inspection, and post-market surveillance. Gene therapy BLAs must address long-term follow-up for potential late effects.
Clinical Trial Phases: Sequential testing stages: Phase 1 (safety, dose-finding, 20-100 healthy volunteers or patients), Phase 2 (efficacy, dose-response, ~100-300 patients), Phase 3 (large-scale confirmation, 300-3000+ patients, randomised controlled trials), Phase 4 (post-market surveillance of approved products). Nanomedicines follow similar phases with additional focus on formulation consistency.
Preclinical Development: Laboratory and animal studies establishing safety and efficacy before human testing. For nanomedicines, this includes physicochemical characterisation, in vitro studies, pharmacokinetics, biodistribution, toxicology, and often disease model efficacy studies. Preclinical data supports IND filing and first-in-human trials.
Pharmacovigilance: Post-market surveillance monitoring approved drugs for adverse events, effectiveness in real-world use, and long-term safety. For nanomedicines and gene therapies, enhanced pharmacovigilance may be required due to novel mechanisms and potential long-term effects. Adverse event reporting is mandatory.
Adverse Event: Any undesirable medical occurrence in patients treated with pharmaceutical products, regardless of causal relationship. Adverse events range from mild (headache, nausea) to severe (organ failure, death). Classification by severity, frequency, and causality guides risk-benefit assessment. Serious adverse events require rapid reporting to regulators.
Off-Target Effects: Unintended interactions of therapeutics with non-target genes, cells, tissues, or molecules causing adverse effects or reduced specificity. Gene therapies face off-target editing concerns; nanoparticles may accumulate in non-target organs. Minimising off-target effects through improved targeting and specificity is crucial for therapeutic index.
Immunogenicity: The propensity of substances to trigger immune responses including antibody production, complement activation, T-cell responses, and cytokine release. Immunogenicity can cause adverse reactions, reduce efficacy through neutralising antibodies, and limit repeat dosing. Assessing immunogenicity through validated assays is required for biologics including gene therapy vectors.
Neutralising Antibodies: Antibodies that bind therapeutics and block their biological activity, reducing or eliminating efficacy. Pre-existing antibodies (e.g., to AAV) or treatment-induced antibodies can prevent gene therapy success. Screening for baseline antibodies and monitoring development during treatment guides patient selection and dosing strategies.
Quality by Design (QbD): Systematic pharmaceutical development approach building quality into products through understanding product/process relationships. QbD includes defining quality target product profile, identifying critical quality attributes, using risk assessment, and establishing design space. QbD is encouraged by regulators and valuable for complex nanomedicines.
Critical Quality Attributes (CQAs): Physical, chemical, biological, or microbiological properties that should be within appropriate limits to ensure product quality. For nanomedicines, CQAs include size, surface charge, drug loading, sterility, endotoxin levels, and potency. Establishing and controlling CQAs throughout manufacturing ensures consistent product quality.
Process Analytical Technology (PAT): Systems for analysing and controlling manufacturing through real-time measurements of critical process parameters, enabling quality assurance. PAT reduces testing time, improves understanding of processes, and aligns with QbD principles. Implementation is challenging but valuable for nanomedicine manufacturing consistency.
Scale-Up and Manufacturing: Translating laboratory-scale production to commercial-scale manufacturing while maintaining quality and consistency. Nanomedicine scale-up faces challenges including maintaining size distribution, drug loading, batch-to-batch reproducibility, and sterility. Continuous manufacturing and automated systems improve scalability and consistency compared to batch processes.
Batch-to-Batch Consistency: Reproducibility of product quality across different manufacturing batches, essential for regulatory approval and clinical safety. For nanomedicines, maintaining consistent size, loading, surface properties, and biological performance between batches is challenging. Robust manufacturing processes, stringent quality control, and validated analytical methods ensure consistency.
Stability Studies: Testing to determine how product quality varies with time under environmental conditions (temperature, humidity, light). ICH guidelines specify stability testing protocols. Nanomedicines face unique stability challenges including aggregation, drug leakage, and surface property changes. Stability data determines shelf life and storage conditions.
Sterilisation: Process eliminating all viable microorganisms to ensure product safety. Traditional sterilisation methods (autoclaving, gamma irradiation, ethylene oxide) may damage sensitive nanomedicines. Sterile filtration through 0.22 μm filters is common but limits particle size. Aseptic manufacturing or alternative sterilisation (e-beam, UV) may be required.
Lyophilisation (Freeze-Drying): Process removing water from frozen samples by sublimation, improving product stability for long-term storage. Many nanomedicines are lyophilised with cryoprotectants (sucrose, trehalose) to prevent aggregation during freezing/drying. Reconstitution must restore original properties. Lyophilisation enables room-temperature storage and global distribution.
Regulatory Pathway Selection: Choosing appropriate regulatory route (FDA, EMA, PMDA) based on product classification (drug, biologic, combination product, device). Nanomedicines may follow different pathways depending on composition and mechanism. Early regulatory consultation helps clarify requirements, accelerating development.
Orphan Drug Designation: Regulatory status for treatments targeting rare diseases (<200,000 US patients), providing incentives including tax credits, grant funding, and market exclusivity. Many gene therapies qualify for orphan designation, accelerating development for rare genetic disorders. Orphan drugs may have streamlined approval pathways.
Breakthrough Therapy Designation: FDA programme expediting development and review of drugs for serious conditions showing substantial improvement over existing treatments. Gene therapies frequently receive breakthrough designation, enabling intensive FDA guidance, rolling review, and priority review. Examples include several approved AAV gene therapies.
Accelerated Approval: Regulatory pathway for serious conditions with unmet need, allowing approval based on surrogate endpoints reasonably likely to predict clinical benefit. Post-approval confirmatory studies verify benefit. Several gene therapies received accelerated approval, providing earlier patient access while confirming long-term outcomes.
Real-World Evidence (RWE): Clinical evidence from non-traditional sources including electronic health records, insurance claims, patient registries, and wearable devices. RWE supplements clinical trial data, particularly for rare diseases where traditional trials are difficult. Regulators increasingly accept RWE for approval decisions and label expansions.
Patient-Reported Outcomes (PROs): Health outcomes directly reported by patients including symptoms, functional status, and quality of life. PROs provide patient perspective beyond clinical measurements, increasingly important for regulatory decisions. Gene therapies for neuromuscular diseases often rely heavily on PROs demonstrating functional improvements.
Risk Evaluation and Mitigation Strategy (REMS): FDA-required risk management plan for drugs with serious safety concerns, ensuring benefits outweigh risks. REMS may include medication guides, communication plans, Elements to Assure Safe Use (ETASU), or implementation systems. Some gene therapies require REMS due to potential serious adverse effects.
Long-Term Follow-Up (LTFU): Extended monitoring after gene therapy for potential delayed adverse effects including insertional mutagenesis, late-onset toxicity, or disease recurrence. FDA recommends 15-year follow-up for integrating gene therapies. LTFU registries track patients long after trials complete, providing crucial safety data.

Advanced Therapeutic Concepts29

CAR-T Cell Therapy: Chimeric Antigen Receptor T-cell therapy where patients' T-cells are genetically engineered to express synthetic receptors recognising cancer antigens, then expanded and reinfused. CAR-T represents a revolutionary cancer immunotherapy with FDA approvals for hematologic malignancies (Kymriah, Yescarta). Major challenges include cytokine release syndrome, neurotoxicity, and high costs.
Chimeric Antigen Receptor (CAR): Synthetic receptor combining antibody-derived antigen recognition with T-cell activation domains, enabling T-cells to target and kill cancer cells in an MHC-independent manner. CARs typically include extracellular targeting domain (scFv), transmembrane domain, and intracellular signalling domains (CD3ζ, costimulatory). Multiple CAR generations with improved designs are being developed.
Cytokine Release Syndrome (CRS): Potentially life-threatening immune overactivation following CAR-T infusion or immunotherapy, characterised by high cytokine levels (IL-6, TNF-α), fever, hypotension, and organ dysfunction. CRS is graded by severity; management includes tocilizumab (anti-IL-6) and corticosteroids. Understanding and managing CRS has improved CAR-T safety.
mRNA Therapeutics: Therapeutic use of messenger RNA to direct cellular protein production without genome integration. mRNA vaccines (COVID-19) demonstrated clinical viability; protein replacement therapies are in development. Advantages include transient expression, no integration risk, and rapid design/manufacturing. Challenges include instability and delivery efficiency.
Self-Amplifying RNA (saRNA): RNA constructs encoding both therapeutic genes and viral replication machinery, amplifying within cells to achieve high protein expression from low doses. saRNA bridges standard mRNA (no amplification) and viral vectors (permanent), offering enhanced potency without integration risks. Applications include vaccines and transient protein expression.
Circular RNA (circRNA): Closed-loop RNA structures lacking 5' and 3' ends, conferring remarkable stability against exonuclease degradation. circRNA can function as protein-coding templates (for sustained expression) or regulatory molecules (miRNA sponges). Their stability makes them attractive for therapeutic applications requiring prolonged expression without repeated dosing.
CRISPR Base Editors: Precision gene editing tools that directly convert one DNA base to another (C→T, A→G) without double-strand breaks, reducing indels and chromosomal rearrangements. Cytosine base editors (CBEs) and adenine base editors (ABEs) expand CRISPR's therapeutic scope, enabling precise correction of point mutations causing genetic diseases.
CRISPR Prime Editors: Advanced editors enabling all base substitutions, insertions, and deletions without requiring double-strand breaks or donor DNA. Prime editors use Cas9 nickase fused to reverse transcriptase guided by prime editing guide RNAs (pegRNAs). This versatility enables correcting virtually any genetic mutation with minimal byproducts.
Epigenome Editing: Technologies modifying gene expression without altering DNA sequence through targeting epigenetic marks (DNA methylation, histone modifications). CRISPR-based epigenome editors (CRISPRa for activation, CRISPRi for silencing) fuse catalytically inactive Cas9 to epigenetic modifiers. Applications include treating diseases caused by aberrant gene expression rather than mutations.
RNA Interference (RNAi): Natural cellular process where small interfering RNAs (siRNAs, 21-23 nucleotides) guide sequence-specific mRNA degradation, silencing gene expression. RNAi therapeutics target disease-causing genes including mutant proteins, viral genes, and overexpressed oncogenes. FDA-approved siRNA drugs include patisiran (TTR amyloidosis) and givosiran (porphyria).
MicroRNA (miRNA) Therapeutics: Therapeutic approaches targeting microRNAs, small non-coding RNAs regulating multiple genes post-transcriptionally. Strategies include miRNA mimics (restoring tumour-suppressor miRNAs) or antimiRs/antagomiRs (blocking oncogenic miRNAs). MiRNA's ability to regulate networks makes it attractive for complex diseases, though specificity is challenging.
Antisense Oligonucleotides (ASOs): Short single-stranded DNA or RNA sequences (15-30 nucleotides) that bind complementary mRNA through Watson-Crick base pairing, modulating gene expression via various mechanisms including RNase H-mediated degradation, splicing modulation, or translational blocking. Multiple ASO drugs are FDA-approved including nusinersen (SMA) and eteplirsen (DMD).
Splice-Switching Oligonucleotides (SSOs): ASOs that modulate pre-mRNA splicing to correct aberrant splicing or skip mutated exons, restoring functional protein production. SSOs have achieved clinical success for spinal muscular atrophy (nusinersen) and Duchenne muscular dystrophy (eteplirsen), demonstrating therapeutic potential for splice-defect diseases.
Peptide Nucleic Acids (PNAs): Synthetic DNA mimics with neutral peptide backbone replacing sugar-phosphate backbone, conferring extraordinary binding affinity, nuclease resistance, and low immunogenicity. PNAs enable antisense therapy, triplex formation, and gene editing. Their neutrality avoids electrostatic repulsion but challenges cellular delivery.
Morpholinos: Synthetic oligonucleotide analogs with morpholine rings replacing ribose and phosphorodiamidate linkages, providing nuclease resistance and low toxicity. Morpholinos primarily modulate splicing or block translation. FDA-approved examples include eteplirsen and golodirsen for Duchenne muscular dystrophy, demonstrating clinical viability for rare genetic disorders.
Locked Nucleic Acids (LNAs): Modified nucleotides with ribose ring "locked" by methylene bridge connecting 2'-oxygen and 4'-carbon, dramatically increasing binding affinity and nuclease resistance. LNA incorporation into oligonucleotides creates highly potent therapeutics with shorter sequences, reducing manufacturing costs and improving properties for ASO and miRNA therapeutics.
Aptamers: Short oligonucleotide or peptide sequences folding into 3D structures that bind specific molecular targets with antibody-like affinity. Nucleic acid aptamers (DNA/RNA) offer advantages including chemical synthesis, low immunogenicity, small size, and ease of modification. Pegaptanib (anti-VEGF aptamer) is FDA-approved for macular degeneration.
DNAzymes and Ribozymes: Catalytic nucleic acids with enzymatic activity, capable of cleaving specific RNA targets. These self-cleaving or trans-acting molecules enable therapeutic gene silencing. While challenges include stability and delivery, chemical modifications improve properties. Ribozymes have been explored for cancer, viral infections, and genetic disorders.
Exosomes: Naturally occurring extracellular vesicles (30-150 nm) secreted by cells, containing proteins, nucleic acids, and lipids. Exosomes mediate intercellular communication and show promise as drug/gene delivery vehicles due to biocompatibility, ability to cross barriers, and natural targeting. Challenges include heterogeneity, scalability, and loading efficiency.
Biomimetic Nanoparticles: Synthetic nanocarriers mimicking natural biological structures or processes to improve delivery efficiency and reduce immunogenicity. Examples include cell membrane-coated nanoparticles, virus-like particles, and exosome-mimetic vesicles. Biomimetic approaches exploit natural biological mechanisms for enhanced therapeutic delivery.
Virus-Like Particles (VLPs): Self-assembling nanostructures composed of viral structural proteins but lacking genetic material, mimicking virus morphology without infectivity. VLPs safely deliver antigens for vaccination (HPV vaccines), can be loaded with drugs/genes, and combine viral delivery efficiency with improved safety compared to viral vectors.
Gene Silencing Therapeutics: Approaches reducing or eliminating target gene expression to treat diseases caused by toxic gain-of-function, dominant mutations, or overexpression. Technologies include RNAi, ASOs, and CRISPR-based methods. Applications span neurodegenerative diseases (huntingtin lowering), cancer (oncogene silencing), and viral infections (HBV suppression).
Protein Replacement Therapy: Treating genetic deficiencies by providing functional protein copies via gene therapy or recombinant protein administration. Gene therapy enables endogenous production from a single treatment vs. repeated protein injections. Examples include Factor IX for hemophilia B and enzyme replacement for lysosomal storage disorders.
Gene Augmentation: Adding functional gene copies to compensate for mutated genes without correcting the original mutation. This is simpler than gene correction and effective for recessive disorders where one functional copy suffices. Approved examples include voretigene neparvovec (RPE65-associated retinal dystrophy) and onasemnogene abeparvovec (spinal muscular atrophy).
In Situ Gene Therapy: Direct administration of therapeutic vectors into target tissues/organs without cell manipulation outside the body. This simplifies procedures and enables treating tissues difficult to harvest/culture. Examples include subretinal injection for inherited retinal diseases and intrathecal delivery for CNS disorders.
Systemic Gene Delivery: Intravenous or other systemic vector administration enabling widespread tissue transduction. Challenges include immune responses, off-target effects, and achieving sufficient target organ levels. AAV9 and engineered capsids enable systemic CNS delivery for neuromuscular diseases, while liver-tropic vectors treat metabolic disorders.
Local Gene Delivery: Direct vector administration to target tissues, maximising local concentration while minimising systemic exposure and off-target effects. Routes include intramuscular, subretinal, intrathecal, and intratumoral injection. Local delivery reduces required doses and immune responses but limits treatment to accessible tissues.
Redosing Strategies: Approaches enabling repeated gene therapy administration to maintain therapeutic levels or treat progressive diseases. Challenges include neutralising antibodies preventing vector transduction. Strategies include immune suppression, capsid switching, empty capsid decoys, and plasmapheresis to remove antibodies.
Germline vs Somatic: Fundamental distinction in gene therapy: somatic targets non-reproductive cells (effects limited to treated individual), while germline modifies reproductive cells or early embryos (heritable changes). Somatic gene therapy is ethically accepted and clinically practiced; germline editing remains prohibited for reproduction in most countries due to ethical and safety concerns.

Emerging Technologies & Future Directions17

Nanorobotics: Design and fabrication of programmable nanoscale devices capable of navigation, sensing, and therapeutic delivery with precision control. DNA origami-based nanorobots can detect disease markers and release drugs upon activation. While still largely preclinical, nanorobotics may eventually enable unprecedented therapeutic precision.
DNA Origami: Technique folding DNA strands into defined 2D/3D nanostructures with nanometer precision, creating platforms for drug delivery, biosensing, and molecular computing. DNA origami's programmability enables creating complex nanodevices with controlled drug release, targeting capabilities, and logic-gate functions responding to multiple inputs.
4D Bioprinting: Advanced additive manufacturing creating structures that transform over time in response to stimuli, adding temporal dimension to 3D printing. For nanomedicine, 4D printing enables creating scaffolds that reshape, degrade, or release drugs in controlled temporal patterns, advancing tissue engineering and drug delivery.
Organ-on-Chip: Microfluidic systems culturing human cells in architectures mimicking organ structure and function, better predicting human responses than traditional models. Organ chips enable testing nanoparticle toxicity, delivery, and efficacy in physiologically relevant conditions, potentially reducing animal testing and improving clinical translation.
Personalised Nanomedicine: Tailoring nanoformulations to individual patients based on genetic profiles, disease characteristics, and biomarkers. Approaches include patient-specific tumour models for testing formulations, genomic screening for optimal gene therapy approaches, and adaptive dosing based on pharmacokinetic monitoring. Precision nanomedicine may dramatically improve treatment outcomes.
Artificial Intelligence in Nanomedicine: Machine learning applications for designing optimised nanoparticles, predicting pharmacokinetics/toxicity, analysing high-throughput screening data, and discovering structure-activity relationships. AI accelerates development by exploring vast design spaces, identifying patterns humans miss, and optimising formulations with fewer experiments.
CRISPR Delivery Innovations: Advanced approaches delivering CRISPR components including lipid nanoparticles, virus-like particles, engineered exosomes, and cell-penetrating peptides. Transient delivery of CRISPR as ribonucleoprotein (RNP) complexes reduces off-target effects and immunogenicity. Novel delivery systems may enable broad CRISPR therapeutic applications beyond ex vivo approaches.
Synthetic Biology Approaches: Engineering biological systems with novel functions for therapeutic delivery including engineered bacteria targeting tumours, synthetic gene circuits sensing disease states and responding, and designed protein cages for drug encapsulation. Synthetic biology expands nanomedicine capabilities beyond traditional chemical/material approaches.
Neurotechnology and Brain-Machine Interfaces: Nanomaterials enabling neural recording, stimulation, and drug delivery with unprecedented precision. Applications include nanoparticle-based neuromodulation, neural electrode coatings, and targeted BBB crossing for neurodegenerative disease treatment. Combining nanomedicine with neurotechnology may revolutionize brain disorder treatment.
Radiopharmaceuticals and Theranostics: Combining radioactive isotopes with targeted delivery systems for simultaneous imaging and therapy. Nanoparticle-based radiopharmaceuticals improve tumour localisation and retention. Theranostic radionuclides enable companion diagnostics guiding treatment decisions and monitoring response.
Combination Nanomedicine: Delivery systems co-encapsulating multiple therapeutic agents to achieve synergistic effects, overcome resistance, or target multiple pathways. Examples include chemotherapy + immunotherapy combinations, gene therapy + small molecule drugs, and rational drug combinations based on systems biology. Combination approaches may overcome limitations of single-agent therapies.
Microbiome-Targeted Therapies: Nanomedicines targeting gut microbiome for treating diseases including inflammatory bowel disease, metabolic disorders, and cancer. Approaches include bacteriophage therapy, probiotic delivery, microbiome modulation, and exploiting bacteria-nanoparticle interactions. Understanding microbiome-nanomedicine interactions opens new therapeutic avenues.
Senolytic Nanomedicine: Targeted delivery systems for senolytic drugs that eliminate senescent cells accumulating with age and contributing to ageing-related diseases. Nanoparticles can specifically target senescent cells using surface markers, improving safety by reducing healthy tissue exposure. Senolytic nanomedicine may address ageing and age-related diseases.
Immunoengineering: Designing nanomaterials that modulate immune responses for vaccination, cancer immunotherapy, autoimmune disease treatment, or transplant tolerance. This includes nanoparticles mimicking pathogens, delivering antigens to specific immune cells, blocking inhibitory signals, or inducing regulatory responses. Immunoengineering represents a paradigm shift from direct pathogen/cancer targeting to harnessing immunity.
Gene Drives: Genetic elements biasing inheritance to spread genes through populations, potentially eliminating disease vectors or invasive species. While controversial and requiring extreme caution, gene drives may eventually address public health challenges. Nanoparticle delivery of gene drive components might enable environmental applications.
Quantum Biology Applications: Exploiting quantum phenomena in biological systems for therapeutic applications. Quantum dots enable superresolution imaging; quantum sensing detects subtle biological signals; quantum computing may solve complex biomolecular problems. As quantum biology matures, nanomedicine applications may emerge.
Space Nanomedicine: Adapting nanomedicine for space exploration challenges including radiation exposure, microgravity effects, resource constraints, and long-duration missions. Nanoformulations enabling long-term stability, minimal storage requirements, and radiation protection may be essential for Mars missions and deep space exploration.

Additional terms2

Enhanced permeability and retention (EPR): The tendency of macromolecules and nanoparticles to accumulate in tumour tissue because of leaky vasculature and impaired lymphatic drainage.
Encapsulation efficiency: The fraction of total payload that is successfully entrapped within the carrier rather than free in solution.

Abbreviations & Acronyms97

AAV: Adeno-Associated Virus
ABC: Accelerated Blood Clearance
ADME: Absorption, Distribution, Metabolism, Excretion
ADC: Antibody-Drug Conjugate
AFM: Atomic Force Microscopy
AgNP: Silver Nanoparticle
ASO: Antisense Oligonucleotide
AuNP: Gold Nanoparticle
BBB: Blood-Brain Barrier
BLA: Biologics License Application
CAR: Chimeric Antigen Receptor
cGMP: Current Good Manufacturing Practice
circRNA: Circular RNA
CLSM: Confocal Laser Scanning Microscopy
CME: Clathrin-Mediated Endocytosis
CNS: Central Nervous System
CNT: Carbon Nanotube
CPP: Cell-Penetrating Peptide
CQA: Critical Quality Attribute
CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats
CRS: Cytokine Release Syndrome
DART: Developmental and Reproductive Toxicity
DLS: Dynamic Light Scattering
DMD: Duchenne Muscular Dystrophy
DNA: Deoxyribonucleic Acid
DSC: Differential Scanning Calorimetry
ECM: Extracellular Matrix
EE: Encapsulation Efficiency
EMA: European Medicines Agency
EPR: Enhanced Permeability and Retention
ETASU: Elements to Assure Safe Use
FDA: Food and Drug Administration
FTIR: Fourier Transform Infrared Spectroscopy
GLP: Good Laboratory Practice
GMP: Good Manufacturing Practice
HSV: Herpes Simplex Virus
IBD: Inflammatory Bowel Disease
ICH: International Council for Harmonisation
IFP: Interstitial Fluid Pressure
IND: Investigational New Drug
LC: Loading Capacity
LDH: Lactate Dehydrogenase
LNA: Locked Nucleic Acid
LNP: Lipid Nanoparticle
LTFU: Long-Term Follow-Up
miRNA: MicroRNA
MOF: Metal-Organic Framework
MPS: Mononuclear Phagocyte System
MRI: Magnetic Resonance Imaging
mRNA: Messenger RNA
MSN: Mesoporous Silica Nanoparticle
MWCNT: Multi-Walled Carbon Nanotube
NDA: New Drug Application
NIR: Near-Infrared
NLC: Nanostructured Lipid Carrier
NLS: Nuclear Localisation Signal
NMR: Nuclear Magnetic Resonance
NP: Nanoparticle
PAT: Process Analytical Technology
PDI: Polydispersity Index
PDT: Photodynamic Therapy
PEG: Polyethylene Glycol
PEI: Polyethylenimine
PET: Positron Emission Tomography
PK: Pharmacokinetics
PLGA: Poly(lactic-co-glycolic acid)
PMDA: Pharmaceuticals and Medical Devices Agency (Japan)
PNA: Peptide Nucleic Acid
PRO: Patient-Reported Outcome
PTT: Photothermal Therapy
QbD: Quality by Design
QD: Quantum Dot
REMS: Risk Evaluation and Mitigation Strategy
RES: Reticuloendothelial System
RNA: Ribonucleic Acid
RNAi: RNA Interference
RNP: Ribonucleoprotein
ROS: Reactive Oxygen Species
saRNA: Self-Amplifying RNA
SAXS: Small Angle X-ray Scattering
SCID: Severe Combined Immunodeficiency
SEM: Scanning Electron Microscopy
shRNA: Short Hairpin RNA
siRNA: Small Interfering RNA
SLN: Solid Lipid Nanoparticle
SMA: Spinal Muscular Atrophy
SSO: Splice-Switching Oligonucleotide
SWCNT: Single-Walled Carbon Nanotube
TALEN: Transcription Activator-Like Effector Nuclease
TEM: Transmission Electron Microscopy
TGA: Thermogravimetric Analysis
TME: Tumour Microenvironment
UCNP: Upconversion Nanoparticle
UV: Ultraviolet
VEGF: Vascular Endothelial Growth Factor
VLP: Virus-Like Particle
XRD: X-Ray Diffraction

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.